Furthermore, cancer cells resist the K-Ras G12C inhibitor by bypassing the growth signal from K-Ras through acquiring additional mutations in various pathways, such as gain of function of ALK, BRAF, and loss of function of NF1 and PTEN mutations [87]. Here, KRAS is linked to cancer.